Anavex Life Sciences Corp (AVXL)

[falconer66a]

Anavex MOA WORKS. PDD and Alzheimer's Next!

When the market figures it out, I believe the PPS will reflect the excellent progress, and how much this supports AVXL's other studies using the S1R receptors.

The results announced today are really fine for girls suffering from Rett syndrome. Now, they have some hope for a more normalized life.

But there's a much bigger factor, for the millions suffering from Parkinson's disease and Alzheimer's disease. For both of those recalcitrant central nervous system (CNS) diseases the unique, particular mechanism of action (MOA) of blarcamesine, binding to and propitiously activating the sigma-1 receptor protein, was still in question. Sure, pre-clinical studies in diseased murines (lab rodents), along with some early safety and tolerability (Phase 1) studies in humans strongly indicated that blarcamesine would be both safe and therapeutic, but both the MOA and the therapeutic results were still in question in humans.

Understandably. All of the murine results from blarcamesine were "too good to be true." No obviating side effects --- extremely uncommon in neuroactive drugs. Then, results too good to be true. Transgenic rats with severe, fully-developed human-genetic Alzheimer's get their cognition rather fully restored. Of course, that was by a similar Anavex drug, Anavex 3-71. But it's MOA is identical to blarcamesine's; acting on the sigma-1 receptor protein.

It is now fully established that in humans the blarcamesine MOA is therapeutically functional. It WORKS. Because of that, the results in the on-going Phase 3 Parkinson's disease dementia and Alzheimer's disease trials will be positive. Medical science will be changed going forward. Sigma-1 receptor protein activation will be quickly entered in the med-school textbooks. In the 1940s it was penicillin and antibiotics. In the 2020s it will be the Anavex drugs and their CNS therapeutics.